BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq
California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...
FierceBiotech13h
BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
KELO2h
BioAge valued at $758 million in debut as investors bet on weight-loss drug frenzy
By Arasu Kannagi Basil and Prakhar Srivastava (Reuters) -Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer ...
BioPharma Dive21h
BioAge prices $198M IPO, validating pivot to obesity drug research
The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.
BioAge seeks nearly $200 million in initial public offering
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
FierceBiotech1d
BioAge Labs aims to raise $180M from IPO, private placement to fund obesity trials
BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...
BioAge valued at $758 mln in debut as investors bet on weight-loss drug frenzy
Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.